Summary & Overview
CPT 4172F: No ESA Prescribed for Anemia in Chronic Kidney Disease
CPT code 4172F documents that a clinician did not prescribe an erythropoiesis-stimulating agent (ESA) for anemia in a patient with chronic kidney disease (CKD). As a performance measure, it captures a clinical decision point around anemia management in CKD and is used in quality reporting and population health monitoring. Nationally, tracking ESA prescribing patterns informs efforts to align treatment with guidelines and avoid unnecessary or potentially harmful therapy.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical intent, typical service setting, and implications for billing and quality measurement. The publication also outlines benchmarks and how payers commonly incorporate the measure into quality programs, summarizes relevant policy updates affecting ESA use in CKD, and provides clinical context on anemia management without prescribing ESAs.
This summary is aimed at clinicians, quality leaders, and billing professionals seeking a national perspective on CPT code 4172F, including how it appears in payer quality frameworks and where it fits within care pathways for CKD-related anemia.
Billing Code Overview
CPT code 4172F indicates that the provider does not prescribe erythropoiesis stimulating agent therapy to treat anemia in a patient with chronic kidney disease (CKD). This measure documents the absence of ESA (erythropoiesis-stimulating agent) prescribing for anemia management in CKD patients.
-
Service type: Clinical quality measure / Medication management decision
-
Typical site of service: Outpatient clinic, nephrology clinic, or other ambulatory care settings where CKD and anemia are managed
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with chronic kidney disease (CKD) being followed in a nephrology clinic or renal specialty practice for management of anemia. The patient has laboratory monitoring including hemoglobin, hematocrit, iron studies, and renal function. During a routine visit the provider documents that erythropoiesis-stimulating agent (ESA) therapy (such as epoetin alfa or darbepoetin alfa) is not prescribed for anemia management because the patient’s hemoglobin is above treatment threshold, there are contraindications (for example recent thromboembolic event), iron deficiency is being treated first, the patient prefers oral iron only, or the anemia is being managed conservatively. The clinical workflow includes review of recent labs, medication history, discussion of risks and benefits of ESA therapy, shared decision-making, and documentation that ESA therapy was considered but not prescribed. Typical sites of service include outpatient nephrology clinic, primary care clinic managing CKD, or dialysis clinic charting notes when decisions about ESA use are documented.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure or other service | Use when an E/M visit addressing other problems is performed the same day the ESA decision is documented |